[Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

AI Summary

An interim phase 3 trial in China found that ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy for advanced EGFR-mutated non-small-cell lung cancer that progressed after EGFR tyrosine kinase inhibitor treatment. The drug showed a manageable safety profile and may offer a new treatment option.

Ruzaltatug rezetecan significantly prolonged PFS compared with chemotherapy, with a manageable safety profile, in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. These data support ruzaltatug rezetecan as a potential treatment option in this setting.